Literature DB >> 8485629

Redirection of arachidonic acid metabolism by ICI D1542: effects on thrombus formation in the coronary artery of the anaesthetized dog.

S J McAuliffe1, J A Moors, H M Snow, M Wayne, R Jessup.   

Abstract

1. The effects of simultaneous redirection of arachidonic acid metabolism, by inhibition of thromboxane A2 (TXA2) synthase and blockade of the platelet thromboxane A2 receptor (TP-receptor), was examined on the rate of thrombus formation in a stenosed coronary artery with damaged endothelium in an anaesthetized dog. 2. Redirection of arachidonic acid metabolism was achieved by intravenous doses of ICI D1542, a selective and potent inhibitor of TXA2 synthase and the TP-receptor. 3. Redirection of arachidonic acid metabolism was demonstrated in whole blood, stimulated ex vivo by collagen. The ED50 for inhibition of TXB2 production was 7.1 micrograms kg-1, i.v.; there were corresponding increases in the production of the eicosanoids prostaglandin D2 (PGD2), PGE2 and PGF2 alpha. 4. Thrombus formation was inhibited by D1542 (ED50 0.55 micrograms kg-1, i.v.), but could be restarted by an intravenous infusion of adrenaline (0.2-38 micrograms kg-1 min-1, i.v.). In the presence of the maximum effective dose of D1542 (1 mg kg-1, i.v.) a 190 fold increase in the infusion rate of adrenaline was required to restore thrombus formation. 5. In the presence of D1542, removal of endoperoxide metabolites by inhibition of cyclo-oxygenase with aspirin (5 mg kg-1, i.v.) caused thrombus formation to restart, indicating the ability of the endoperoxide metabolites to inhibit thrombus formation in vivo. 6. These results indicate that, in the stenosed and damaged coronary artery of the dog, redirection of arachidonic acid metabolism by D1542 is more effective at preventing thrombus formation than inhibition of cyclo-oxygenase by aspirin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485629      PMCID: PMC1908127          DOI: 10.1111/j.1476-5381.1993.tb13484.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  5 in total

1.  Platelet aggregation in partially obstructed vessels and its elimination with aspirin.

Authors:  J D Folts; E B Crowell; G G Rowe
Journal:  Circulation       Date:  1976-09       Impact factor: 29.690

2.  Novel alpha2-adrenoreceptors primarily responsible for inducing human platelet aggregation.

Authors:  J A Grant; M C Scrutton
Journal:  Nature       Date:  1979-02-22       Impact factor: 49.962

3.  Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.

Authors:  S K Yao; M Rosolowsky; H V Anderson; P Golino; J M NcNatt; F De Clerck; L M Buja; J T Willerson
Journal:  J Am Coll Cardiol       Date:  1990-09       Impact factor: 24.094

4.  Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions.

Authors:  G H Rao; G Escolar; J G White
Journal:  Thromb Res       Date:  1986-10-01       Impact factor: 3.944

5.  Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.

Authors:  I S Watts; K A Wharton; B P White; P Lumley
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

  5 in total
  3 in total

1.  Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.

Authors:  S J McAuliffe; J A Moors; H B Jones
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 2.  Antiplatelet drugs. A comparative review.

Authors:  K Schrör
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

3.  Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin.

Authors:  Marilena Crescente; Paul C Armstrong; Nicholas S Kirkby; Matthew L Edin; Melissa V Chan; Fred B Lih; Jing Jiao; Tania Maffucci; Harriet E Allan; Charles A Mein; Carles Gaston-Massuet; Graeme S Cottrell; Jane A Mitchell; Darryl C Zeldin; Harvey R Herschman; Timothy D Warner
Journal:  FASEB J       Date:  2020-06-27       Impact factor: 5.834

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.